Description

OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C42H62N14O9—-[1]Dong J, et.al. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem. 2023 Jun 22;66(12):8251-8266. —-907.03–95.95–O[C@H](C)[C@@H](C(N1)=O)NC([C@H](CC2=CNC3=CC=CC=C32)NC([C@@H]4CCCN4C([C@H](CCCNC(N)=N)NC([C@H](CC5=CNC=N5)NC([C@H](CCCCN)NC([C@@H]1[C@H](O)C)=O)=O)=O)=O)=O)=O–Others–DMSO : 100 mg/mL (ultrasonic)–EGFR;STAT–STAT3–JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt–Peptides